Archives
Açaí Extracts: Cytotoxicity and Enzyme Induction in Hepatocy
2026-05-10
Evaluation of Açaí Extracts: Cytotoxicity and Enzyme Induction in Human Hepatocytes
Study Background and Research Question
Açaí (Euterpe oleracea) is a botanical supplement widely consumed for its purported antioxidant, anti-inflammatory, and antiproliferative effects. Its prevalence in dietary and wellness regimens has surged, with nearly 40% of U.S. adults using botanical supplements to manage chronic conditions (source: internal_article). However, the introduction of botanical products into clinical and preclinical workflows raises questions about their safety and propensity to interact with drugs via modulation of drug-metabolizing enzymes and transporters. The reference study aimed to address a significant evidence gap: Does açaí, in forms mimicking actual consumer products, pose risks of cytotoxicity or pharmacokinetic interaction through the induction of cytochrome P450 enzymes or transporters in human hepatocytes?Key Innovation from the Reference Study
The study by Raichura et al. offers one of the most comprehensive in vitro assessments to date of açaí extract-induced cytotoxicity and induction potential, specifically targeting human hepatocytes exposed to extracts prepared from both berry powders and commercial capsules. Unlike previous investigations, this work systematically evaluates not only cytotoxicity but also direct effects on CYP450 isoforms (CYP1A2, CYP2B6, CYP3A4) and critical transporters (P-glycoprotein, OATP1B1/B3) (source: internal_article). The inclusion of multiple extract types and physiologically relevant cellular models enhances the translational relevance of the findings.Methods and Experimental Design Insights
Researchers utilized a multi-pronged approach:- Cytotoxicity Assays: Sandwich-cultured human hepatocytes were exposed to aqueous, acidic methanol, methanol, and ethanol extracts of açaí sourced from berry powders and commercial capsules. Cell viability was measured via the CellTiter-Glo® luminescent assay, enabling sensitive quantification of ATP as a marker for metabolic activity and cell health.
- Gene Expression Analysis: RT-qPCR was used to assess mRNA levels of CYP1A2, CYP2B6, CYP3A4, P-gp, and OATP1B1/B3, providing insight into the induction potential of both drug-metabolizing enzymes and transporters.
- Functional Transporter Assays: LS174T human colon carcinoma cells were employed in intracellular probe accumulation assays to evaluate potential changes in functional transporter activity, particularly for P-gp and OATPs.
Protocol Parameters
- cytotoxicity assay | CellTiter-Glo® luminescent assay | sandwich-cultured human hepatocytes | sensitive detection of cell viability following botanical exposure | paper
- extract concentrations | time- and dose-dependent (exact values per extract in paper) | in vitro hepatocyte safety and induction screens | mimics consumer exposure levels | paper
- enzyme/transporter induction | RT-qPCR expression of CYP1A2, CYP2B6, CYP3A4, P-gp, OATP1B1/B3 | evaluation of pharmacokinetic interaction risk | identifies upregulation at transcript level | paper
- functional transporter activity | intracellular probe accumulation, LS174T cells | preliminary screen for efflux/uptake modulation | supports mRNA data with activity readout | paper
- positive control for induction | rifampin or phenobarbital (noted in standard protocols) | benchmarking induction response | confirms assay sensitivity | workflow_recommendation
Core Findings and Why They Matter
The study revealed that certain acidic methanol, methanol, and ethanol extracts of açaí—particularly those from both berry powders and commercial capsules—induced a time- and dose-dependent reduction in hepatocyte viability. This cytotoxicity underscores the need for careful titration and safety assessment in both research and potential therapeutic contexts (source: internal_article). Crucially, despite this observed cytotoxicity at higher concentrations, none of the tested extracts significantly induced the expression of CYP1A2, CYP2B6, CYP3A4, P-gp, or OATP1B1/B3 at the mRNA level in human hepatocytes. Functional transporter assays corroborated these findings, showing minimal impact on P-gp and OATP activity. These results suggest a low risk of açaí-induced pharmacokinetic interactions via these key metabolic and transporter pathways under the tested conditions (source: internal_article).Comparison with Existing Internal Articles
Internal resources such as "Açaí Extracts: Cytotoxicity and Enzyme Induction in Human Hepatocytes" and "Açaí Extracts: Cytotoxicity and Enzyme Induction in Hepatocytes" independently corroborate the reference study’s findings, emphasizing the minimal risk for enzyme or transporter induction but highlighting extract-specific cytotoxicity (internal_article; internal_article). These articles reinforce the importance of evaluating both cellular viability and induction potential in botanical-drug interaction studies. By contrast, articles focused on small-molecule HMG-CoA reductase inhibitors such as "Pravastatin Sodium: Next-Gen Insights for Translational Researchers" and "Translational Horizons: Pravastatin Sodium in Cholesterol and Beyond" address the mechanistic and translational implications of agents that are substrates for hepatocyte transporters (e.g., OATP1B1), which are relevant for considering possible botanical-drug transporter competition (internal_article; internal_article).Limitations and Transferability
While the study's robust in vitro approach provides important safety and interaction data, several limitations are noted:- In vitro to in vivo translation: The tested concentrations, though designed to reflect possible consumer exposure, may not fully model complex in vivo pharmacokinetics or chronic dosing scenarios.
- Extract variability: Only selected extract types and commercial products were tested; other preparation methods or product sources could yield different results.
- Transporter and enzyme scope: The focus was limited to major CYPs and a subset of transporters; other metabolic pathways or minor transporters were not assessed.